Loading...
Research and standardization in Alzheimer's trials: Reaching international consensus
Carillo, Maria C. Rowe, Christopher C. Szoeke, Cassandra Masters, Colin L. Ames, David O'Meara, Timothy Macaulay, S Lance Milner, Andrew Ellis, Kathryn A. Maruff, Paul Thomas
Carillo, Maria C.
Rowe, Christopher C.
Szoeke, Cassandra
Masters, Colin L.
Ames, David
O'Meara, Timothy
Macaulay, S Lance
Milner, Andrew
Ellis, Kathryn A.
Maruff, Paul Thomas
Abstract
Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In response to the emerging need for standardization, an international meeting of AD researchers was held in Melbourne, Australia, in March 2012 to bring together key researchers, clinicians, industry, and regulatory stakeholders with the aim of generating consensus on standardization and validation of cognitive, imaging, and fluid biomarkers, as well as lifestyle parameters used in research centers worldwide.
Keywords
Alzheimer's disease, Diagnosis, Early detection, Biomarkers, Clinical outcomes, Cerebral spinal fluid, Amyloid imaging, Magnetic resonance imaging
Date
2013
Type
Journal article
Journal
Alzheimer's and Dementia
Book
Volume
Issue
Page Range
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
License
File Access
Controlled